Skip to main content
Journal of Patient-Reported Outcomes
Fig. 2 | Journal of Patient-Reported Outcomes

Fig. 2

From: Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Fig. 2

Mean change in SNOT-22 score by VAS anchor in total ITT population. Overall VAS anchor groups were defined by change in overall VAS symptom score from baseline to Week 52: moderate to major improvement: ≤  − 4-point change in VAS score; minimal meaningful improvement: ≤ − 2 to > − 4-point change in VAS score; limited improvement or worsening (stable): > − 2 to < 2− point change in VAS score; CDF Cumulative distribution function, CI Confidence interval, ITT Intent-to-treat, SNOT-22 Sino-nasal outcome test-22, VAS Visual analogue scale

Back to article page